

Special Issue

Glioma: From Intracellular Oncogenic Pathways to Targeting Therapeutic Strategies

Message from the Guest Editor

Gliomas are the most common and aggressive type of primary brain tumors originating from glial cells. Key oncogenic pathways such as PI3K/AKT/mTOR, MAPK/ERK, and Notch are critically involved in glioma growth, survival, invasion, and treatment resistance. Genetic and epigenetic modifications, including mutations in IDH1/2, EGFR amplification, and methylation of the MGMT promoter, play crucial roles in tumor behavior and patient prognosis. The challenges of developing effective treatments due to glioma's highly heterogeneous nature and the presence of the blood–brain barrier. Traditional therapies like surgery, radiation, and chemotherapy (e.g., temozolomide) often face limitations due to resistance mechanisms and recurrence. Recent advances include molecularly targeted therapies, such as inhibitors of key pathways (e.g., EGFR inhibitors, PI3K/mTOR inhibitors), immunotherapy approaches (e.g., CAR T-cell therapy, immune checkpoint inhibitors), and novel drug delivery systems like nanocarriers to cross the BBB. Moreover, personalized medicine approaches and combination therapies are emphasized for their potential to enhance treatment efficacy and patient outcomes.

Guest Editor

Dr. Shilpi Singh

Department of Neurosurgery, University of Minnesota, Minneapolis, MN 55455, USA

Deadline for manuscript submissions

31 October 2026



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/221133

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)